Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, llc - atorvastatin calcium (unii: 48a5m73z4q) (atorvastatin - unii:a0jwa85v8f) - atorvastatin 80 mg - therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. in patients with chd or multiple risk factors for chd, atorvastatin calcium tablets can be started simultaneously with diet. in adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low hdl-c, or a family history of early coronary heart disease, atorvastatin calcium tablets is indicated to: - reduce the risk of myocardial infarction - reduce the risk of stroke - reduce the risk for revascularization procedures and angina in patients with type 2 diabetes, and without clinically evident coronary heart disease, but w

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, llc - atorvastatin calcium (unii: 48a5m73z4q) (atorvastatin - unii:a0jwa85v8f) - atorvastatin 40 mg - therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. in patients with chd or multiple risk factors for chd, atorvastatin calcium tablets can be started simultaneously with diet. in adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low hdl-c, or a family history of early coronary heart disease, atorvastatin calcium tablets is indicated to: - reduce the risk of myocardial infarction - reduce the risk of stroke - reduce the risk for revascularization procedures and angina in patients with type 2 diabetes, and without clinically evident coronary heart disease, but w

Καναδάς - Αγγλικά - Health Canada

mylan pharmaceuticals ulc - atorvastatin (atorvastatin calcium); amlodipine (amlodipine besylate) - tablet - 20mg; 5mg - atorvastatin (atorvastatin calcium) 20mg; amlodipine (amlodipine besylate) 5mg - hmg-coa reductase inhibitors

Καναδάς - Αγγλικά - Health Canada

pharmascience inc - atorvastatin (atorvastatin calcium) - tablet - 10mg - atorvastatin (atorvastatin calcium) 10mg - hmg-coa reductase inhibitors

Καναδάς - Αγγλικά - Health Canada

pharmascience inc - atorvastatin (atorvastatin calcium) - tablet - 20mg - atorvastatin (atorvastatin calcium) 20mg - hmg-coa reductase inhibitors

Καναδάς - Αγγλικά - Health Canada

pharmascience inc - atorvastatin (atorvastatin calcium) - tablet - 40mg - atorvastatin (atorvastatin calcium) 40mg - hmg-coa reductase inhibitors

Καναδάς - Αγγλικά - Health Canada

pharmascience inc - atorvastatin (atorvastatin calcium) - tablet - 80mg - atorvastatin (atorvastatin calcium) 80mg - hmg-coa reductase inhibitors

Καναδάς - Αγγλικά - Health Canada

dominion pharmacal - atorvastatin (atorvastatin calcium) - tablet - 10mg - atorvastatin (atorvastatin calcium) 10mg - hmg-coa reductase inhibitors

Καναδάς - Αγγλικά - Health Canada

dominion pharmacal - atorvastatin (atorvastatin calcium) - tablet - 20mg - atorvastatin (atorvastatin calcium) 20mg - hmg-coa reductase inhibitors

Καναδάς - Αγγλικά - Health Canada

dominion pharmacal - atorvastatin (atorvastatin calcium) - tablet - 40mg - atorvastatin (atorvastatin calcium) 40mg - hmg-coa reductase inhibitors